30923-64-9Relevant academic research and scientific papers
Synthesis method of multi-ring double-substituted 1,3 -propanedione compound (by machine translation)
-
Paragraph 0029-0034; 0049-0056; 0099-0111, (2020/07/02)
The synthesis method comprises the following steps: under the protection of an inert gas, reacting the compound represented by the formula II with the compound of formula III under 1,3 - 1,3 - under the protection of inert gas to obtain the compound shown
NEW CRTH2 ANTAGONISTS
-
Page/Page column 161, (2013/03/26)
The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.
PYRAZOLE DERIVATIVES AS MODULATORS OF CALCIUM RELEASE -ACTIVATED CALCIUM CHANNEL
-
Page/Page column 58, (2011/04/26)
Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.
Compounds Useful In Therapy
-
Page/Page column 17, (2008/06/13)
Compounds of Formula (I): and pharmaceutically acceptable salts, solvates (including hydrates) of said compounds and salts, or prodrugs of said compound, or pharmaceutically acceptable salts or solvates of said prodrugs, wherein the substituents are as herein defined, are useful in therapy, for example they may be useful for treating progesterone-mediated conditions such as endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.
COMPOUNDS USEFUL IN THERAPY
-
Page/Page column 17, (2010/11/27)
Compounds of formula (I), or a pharmaceutically acceptable derivative thereof, wherein R1 and R3 independently represent H, C1-6alkyl, C3-8cycloalkyl, or halogen; R2 represents C1-6alkyl, CF3 or aryl; a represents 1 or 2; R4, R5, R7 and R8 independently represent H, C1-6alkyl, C1-6alkyloxy, CN or halogen, or R4 and R5, or R7 and R8, together with the ring to which they are attached form an aryl or heterocyclic fused ring system; X represents C or N; Y represents CH2 or O; R6 represents H, CN or halo provided that, when X represents N, R6 is absent. The compounds are useful for treating endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.
Compounds useful in therapy
-
Page/Page column 21, (2008/06/13)
Compounds of formula (I), [image] or pharmaceutically acceptable derivatives thereof, wherein: R1 represents H, C1-6-alkyl, C1-6alkyloxy, C3-8cycloalkyl, or halo; R2 represents H, C1-6alkyl (optionally substituted by R3), phenyl (optionally substituted by CN), or Het; R3 represents OH, CN, Het, —R4—C1-6alkyl, or CONR5R6; R4 represents —CO2—, or —O—; R5 and R6 independently represent H, C1-6alkyl (optionally substituted by OR7) or C3-8cycloalkyl; R7 represents H or C1-6alkyl; Het represents a five or six membered aromatic heterocyclic group containing (i) from one to four nitrogen heteroatom(s) or (ii) one or two nitrogen heteroatom(s) and one oxygen or one sulphur heteroatom or (iii) one or two oxygen or sulphur heteroatom(s), said heterocyclic group being optionally substituted by one or more groups selected from CN and C1-6 alkyl; R8 represents C1-6alkyl, C1-6alkyloxy, C3-8cycloalkyl, or halo; R9 and R10 independently represent H, C1-6alkyl, C1-6alkyloxy, CN, CF3 or halo; may be useful for treating endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.
PROCESS FOR THE PREPARATION OF 1,3-DICARBONYL COMPOUNDS
-
, (2008/06/13)
The condensation reaction of a ketone with either an ester or a carbonate to form, respectively, a 1,3-diketone or a beta -ketoester often affords poor results under the standard condensation reaction conditions. High yields and high purities of the desired product can be obtained by performing the reaction using an alkoxide base in DMSO as the sole solvent.
Process for the preparation of 1,3-dicarbonyl compounds
-
, (2008/06/13)
The condensation reaction of a ketone with either an ester or a carbonate to form, respectively, a 1,3-diketone or a beta -ketoester often affords poor results under the standard condensation reaction conditions. High yields and high purities of the desir
3,5-Cycloalkyl pyrazolium salts as fungicides
-
, (2008/06/13)
There is provided a method for the control of plant pathogenic fungi with certain 3(5) or 3,5-cycloalkyl pyrazolium salts and to a method of protecting plants from fungal attack by applying to the foliage of said plants said pyrazolium salt in fungicidall
